BioPharmSignal logoBioPharmSignal

Biotech News

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Arbutus (ABUS)ArbutusEarnings

Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran Dr. Roger Sawhney joins the Arbutus Board of Directors following resignation of Anuj Hasija Dr. Harry Janssen joins the Arbutus Scientific Advisory Board Strong financial

Related news

ABUSArbutus2026-08-12 11:30 EST

Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update

ABUSArbutus2026-05-13 11:30 EST

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

SCYXSCYNEXIS2026-08-10 20:30 EST

SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update

BRNSBarinthus Biotherapeutics2026-08-06 12:00 EST

Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments

BNTXBioNTech2026-08-04 10:45 EST

BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update

BNTXBioNTech2026-07-21 10:45 EST

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

SCYXSCYNEXIS2026-05-11 20:23 EST

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

BRNSBarinthus Biotherapeutics2026-04-30 11:30 EST

Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments

ANTXAN2 Therapeutics2026-08-11 20:00 EST

AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights

IMNNImunon2026-08-11 12:00 EST

IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update

View all latest news

Arbutus

Hepatitis B Therapeutics Arbutus Biopharma develops therapies intended to achieve a functional cure for chronic hepatitis B. Its current clinical strategy centers on suppressing viral antigen production with RNA interference. Imdusiran Imdusiran is an RNA interference therapeutic that reduces production of hepatitis B viral proteins,...

Recent company news

ABUSArbutus2026-08-24 11:30 EST

Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share

ABUSArbutus2026-08-21 11:30 EST

Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer

ABUSArbutus2026-08-12 11:30 EST

Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update

ABUSArbutus2026-07-16 11:30 EST

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders

ABUSArbutus2026-05-13 11:30 EST

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

Stock data

Close
5.21 USD
Market cap
841.51M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States